No Data
Aclaris Therapeutics Announces Sale of OLUMIANT Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
PDF VersionAclaris Therapeutics Announces Sale of OLUMIANT Royalties and Milestones to OMERS Life Sciences for Up to $31.5 MillionJuly 16, 2024
Aclaris Therapeutics Secures Deal With OMERS for OLUMIANT Royalties
Aclaris Therapeutics Received $26.5 M Upfront Plus Is Eligible for Up to $5M in Milestones >ACRS
Aclaris Therapeutics Received $26.5 M Upfront Plus Is Eligible for Up to $5M in Milestones >
Express News | Aclaris Therapeutics Shares Are Trading Higher After the Company Announced the Sale of OLUMIANT Royalties and Milestones to OMERS Life Sciences for up to $31.5 Million
Aclaris Sells Portion of Future Royalty Payments and Milestones From Eli Lilly on Sales of OLUMIANT for Alopecia Areata to OMERS
Aclaris Sells Portion of Future Royalty Payments and Milestones From Eli Lilly on Sales of OLUMIANT for Alopecia Areata to
Express News | Aclaris Therapeutics Inc - Receives $26.5M Upfront Payment